Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Both Johnson & Johnson JNJ and Merck MRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...